



## Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

August 29, 2016

[Download this Press Release](#)

WATERTOWN, Mass.--(BUSINESS WIRE)--Aug. 29, 2016-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a business overview and an update on Enanta's research and development pipeline at each of the following investor conferences:

- **September 8, 11:25 a.m. ET – Baird 2016 Global Healthcare Conference, New York City**
- **September 12, 9:20 a.m. ET – Morgan Stanley Global Healthcare Conference, New York City**

A live webcast and replay of each presentation will be accessible by visiting the "Calendar of Events" section on the "Investors" page of Enanta's website at [www.enanta.com](http://www.enanta.com). The webcast replay will be available following each presentation and will be archived for approximately 30 days.

### About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta's research and development is currently focused on four disease targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV).

Enanta has developed direct-acting-antiviral (DAA) inhibitors designed for use against HCV. Enanta's protease inhibitors, developed through its collaboration with AbbVie, include paritaprevir, which is contained in AbbVie's marketed DAA regimens for HCV, and ABT-493, Enanta's second protease inhibitor, which AbbVie is developing in phase 3 studies in combination with ABT-530, AbbVie's NS5A inhibitor. Enanta has also discovered a cyclophilin inhibitor, EDP-494, a novel, host-targeting mechanism for HCV, which is now in phase 1 clinical development, and EDP-305, an FXR agonist, which Enanta plans to advance into clinical development for NASH later in 2016. In addition, Enanta has early lead candidates for HBV and RSV in preclinical testing. Please visit [www.enanta.com](http://www.enanta.com) for more information on Enanta's programs and pipeline.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160829005049/en/>

Source: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.  
Carol Miceli, 617-607-0710  
[cmiceli@enanta.com](mailto:cmiceli@enanta.com)